Protocatechuic acid

SKU: orb1310493

Description

Protocatechuic acid (3,4-Dihydroxybenzoic acid) is a natural phenolic compound with demonstrated antioxidant properties, including free radical scavenging and upregulation of detoxifying enzymes. It is widely used in cardiovascular and oncology research, with applications in both in vitro and in vivo studies investigating its protective mechanisms.

Research Area

Metabolism Research

Key Properties

• CAS Number: 99-50-3
• MW: 154.12
• Purity: 99.85%
• Formula: C₇H₆O₄
• SMILES: C(O)(=O)C1=CC(O)=C(O)C=C1
• Target: Endogenous Metabolite,Others
• Solubility: H2O:5 mg/mL (32.44 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (12.98 mM);DMSO:96 mg/mL (622.89 mM)

Bioactivity

• In Vivo:
  Protocatechuic acid can prevent stress-induced immobility time in forced swim test without altering locomotor activity in mice. In addition, Protocatechuic acid treatment attenuates the elevation of serum corticosterone, lipid peroxidation and restores enzymatic antioxidants in cerebral cortex and hippocampus in ARS mice. Rat administered cadmium and treated with prostigmine and doses of Protocatechuic acid (10−20 mg/kg) has significantly reduced BChE activity. Cadmium and either prostigmine or Protocatechuic acid (10−20 mg/kg) treated rats shows a marked reduction in MDA level.
• In Vitro:
  Protocatechuic acid inhibits the aggregation of Aβ and αS and destabilizes their preformed fibrils that prevent the death of PC12 cells triggered by Aβ- and αS-induced toxicity.
• Cell Research:
  Protocatechuic acid is dissolved in DMSO. Dilutions of Protocatechuic acid (2, 5, 10, 20, 50, and 100 μM) are prepared from stock solutions, with serum-free culture medium. Equal volumes of each solution are mixed with Aβ1-42 (10 μM), then incubated for 24 h on a thermoblock, with continuous agitation, and then exposed to PC12 cells for 24 h to test whether Protocatechuic acid can prevent cell death triggered by Aβ. Cell viability is determined by MTT reduction assay. Cells are treated with 200 μL per well of MTT solution (final concentration, 0.5 mg/mL in DMEM-Glutamax medium) for 3 h, at 37°C, with 5% CO2. The dark blue formazan crystals that formed are solubilized with 100 μL per well of DMSO, for 30 min. Absorbance is measured at 540 nm, with a microplate reader. Results are expressed as the percentage of MTT reduction in relation to the absorbance of control cells at 100%.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

3, 4-Dihydroxybenzoic acid, 3,4-Dihydroxybenzoic acid, Inhibitor, inhibit, free radical, Endogenous Metabolite, Protocatechuate, Protocatechuic acid

Compound Identifiers

PubChem CID

72